Although it has been reported about the effectiveness of KPT-330 on a CML patient who become IM-resistant26, our evidence was directly obtained from the one with BCR-ABL T315I mutation, the pivotal genetic event occurring during IM-resistance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.